KLK3 and prostate carcinoma: Another parameter used to determine the benefit of drug therapy for CRPC established by the Prostate Cancer Clinical Trials Working Group 2 is time to disease progression; which is a measurement related to consecutive elevated readings of PSA from baseline [7].